2015/2016 HESTIA 1 – Multicenter, Open-label, Randomized, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging, Phase 2 Study of Ticagrelor followed by a Double-blind, randomized, Parallel group, Placebo-controlled 4 weeks extension Phase in Pediatric Patients with Sickle Cell Disease

By Kevin27/04/2024November 19th, 2024No Comments

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.

Previous Post2012 TADO – A phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease
Next Post2018 HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months, with Sickle Cell Disease